Craig Tendler was appointed Director of Parabilis Medicines, Inc. As of November 6, 2026, Parabilis Medicines, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on August 25, 2026, naming 1 appointment (Form 8-K, August 25, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Parabilis Medicines, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Parabilis Medicines, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-08-25. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Parabilis Medicines, Inc. files it.
Also on the record for Parabilis Medicines, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G, by ARCH Venture Fund XII, L.P. | 5.3% of the class | 5%+ stakes | Source |
| August 6, 2026 | Stake report, Schedule 13G, by FMR LLC | 8.5% of the class | 5%+ stakes | Source |
| June 18, 2026 | Stake report, Schedule 13D, by RA Capital Management, L.P. | 23.8% of the class | 5%+ stakes | Source |
| June 10, 2026 | IPO filing, Form 424B4 | $20 a share | IPO filings | Source |
| June 9, 2026 | IPO filing, Form S-1/A | — | IPO filings | Source |
| June 4, 2026 | IPO filing, Form S-1/A | — | IPO filings | Source |
| May 27, 2026 | IPO filing, Form S-1/A | — | IPO filings | Source |
| May 19, 2026 | IPO filing, Form S-1 | — | IPO filings | Source |
Selling to them or working with them? See who runs Parabilis Medicines, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Parabilis Medicines, Inc. and the records around it.
Parabilis Medicines, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- ARCH Venture Fund XII, L.P. also filed stake reports on 5 other companies: City Therapeutics, Inc. (Oct 2026), Seaport Therapeutics, Inc. (May 2026), Neumora Therapeutics, Inc. (Apr 2026)
- RA Capital Management, L.P. also filed stake reports on 100 other companies: Climb Bio, Inc. (Nov 2026), Bambusa Therapeutics, Inc. (Nov 2026), SOLID BIOSCIENCES INC. (Nov 2026)
- FMR LLC also filed stake reports on 761 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
Watch Parabilis Medicines, Inc.
Get an email when Parabilis Medicines, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Parabilis Medicines, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Parabilis Medicines, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Parabilis Medicines, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-08-25 | In | Director | 8-K, 2026-08-25 |
Who leads Parabilis Medicines, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Craig Tendler, appointed (filed 2026-08-25).
New leaders reset buying decisions — get the Full Report on Parabilis Medicines, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Parabilis Medicines, Inc., with the record behind each one.
Find candidates like Director at Parabilis Medicines, Inc.Every change, in the filing's words
Appointed: Craig Tendler, Director
On August 22, 2026, the Board of Directors (the "Board") of Parabilis Medicines, Inc. (the "Company") increased the number of directors of the Company to nine (9) and appointed Craig Tendler as a director of the Company to fill the newly created vacancy.
- Mr. Tendler was appointed to serve as a Class II director until his term expires at the 2028 annual meeting of stockholders.
- The Board determined that Mr. Tendler is independent under the listing standards of The Nasdaq Stock Market.
- The Board also approved the appointment of Mr. Tendler as a member of the Science & Technology Committee of the Board (the "Science & Technology Committee").
- In accordance with the Company's compensation program for non-employee directors, Mr. Tendler received an equity award consisting of a stock option to purchase 20,294 shares of the Company's common stock at an exercise price of $39.36 per share.
- The option award will vest in thirty-six substantially equal monthly installments over three years from the date of grant, provided, however, that all vesting will cease if Mr. Tendler ceases to serve on the Board.
- In accordance with the Company's compensation program for non-employee directors, Mr. Tendler will also receive an annual retainer of $40,000 for Board service and $7,500 for Science & Technology Committee service, each to be paid quarterly in arrears, pro-rated based on the number of actual days served by the director during such calendar quarter.
Tools for this story
Each opens in a new tab, filled in for Parabilis Medicines, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.